Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05735639 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Study acronym: THRIVE
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment reduced: 6660 → 3175 participantsv9
  2. Primary completion date: Jun 30, 2026 to Jun 30, 2027 Completion date: Dec 31, 2026 to Dec 31, 2027v8 Show 1 more changeShow less
    • Completion date: Dec 31, 2026 to Dec 31, 2027
  3. Re-verified, no change to tracked fieldsv7
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jan 1, 2024 to Jan 22, 2024 · Site details revisedv6 Show 2 more changesShow less
    • Start date changed from estimate of Jan 1, 2024 to Jan 22, 2024
    • Site details revised
  5. Start date: Oct 1, 2023 to Jan 1, 2024 Eligibility criteria expanded, about 9 words · Secondary endpoints revised (8)v5 Show 2 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints revised (8)

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Secondary endpoints revised (8)v4 See this version in full on ClinicalTrials.gov ↗
  2. Start date: Jun 1, 2023 to Oct 1, 2023 Primary completion date: Jun 1, 2026 to Jun 30, 2026 · Completion date: Aug 31, 2026 to Dec 31, 2026 · Eligibility criteria expanded, about 42 words · 1 morev3 Show 4 more changesShow less
    • Primary completion date: Jun 1, 2026 to Jun 30, 2026
    • Completion date: Aug 31, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: 4 to 8

    See this version in full on ClinicalTrials.gov ↗

  3. Eligibility criteria expanded, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening. Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures. This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.
Trial Details
NCT Number NCT05735639
Lead Sponsor Imperial College London
Conditions Venous Thromboembolism, Varicose Veins
Enrollment 3,175 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov